Adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in HER2-positive breast cancer

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Trastuzumab + pertuzumab may improve pCR outcomes in HER2-positive breast cancer patientsПодробнее

SABCS 2017: Adjuvant Trastuzumab Did Not Improve Outcomes for Patients With HER2-low Breast CancerПодробнее

Optimizing treatment in patients with early-stage HER2-positive breast cancerПодробнее

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancerПодробнее

Adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in HER2-positive breast cancerПодробнее

2014 DDF Stomach Cancer Education Symposium - Clinical Trials - David H. Ilson, MD, PhDПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Raising the Bar in HER2-Positive Breast CancerПодробнее

Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancerПодробнее

Adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in HER2-positive breast cancerПодробнее

HER2+ Breast Cancer: Neratinib’s Role as Adjuvant TherapyПодробнее

Optimizing adjuvant treatment in HR+/HER2- early breast cancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Traina & Dr. CareyПодробнее

5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BCПодробнее

Role of Lapatinib in HER2-Positive Breast CancerПодробнее

Improving Long-Term Outcomes in HER2+ Breast CancerПодробнее

Anti-HER2 strategies in breast cancer: the ALTTO trialПодробнее

Dr. Blackwell Discusses Tucatinib in HER2+ Breast CancerПодробнее

Adjuvant Strategies in Early-Stage HER2+ Breast CancerПодробнее

Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancerПодробнее